Alpha 2.0
Login Register
» Articles » PMID: 34989940

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2022 Jan 6
PMID 34989940
Citations 12
Authors
Nina Tamirisa
Kelly K Hunt
Affiliations
Soon will be listed here.
Citing Articles

Delta dual‑region DCE-MRI radiomics from breast masses predicts axillary lymph node response after neoadjuvant therapy for breast cancer.

Zeng Q, Deng Y, Nan J, Zou Z, Yu T, Liu L BMC Cancer. 2025; 25(1):264.

PMID: 39953506 PMC: 11827315. DOI: 10.1186/s12885-025-13678-z.

UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation.

Long L, Wang L, Liang Y, Ye F, Jin Y, Luo D Transl Oncol. 2024; 52():102241.

PMID: 39674092 PMC: 11700287. DOI: 10.1016/j.tranon.2024.102241.

Low-intensity pulsed ultrasound combined with microbubble mediated JNK/c-Jun pathway to reverse multidrug resistance in triple-negative breast cancer.

Qu N, Wu Z, Meng Q, Bi M, Liu H, Cao X Sci Rep. 2024; 14(1):27250.

PMID: 39516537 PMC: 11549295. DOI: 10.1038/s41598-024-78272-y.

Peripheral NK cell count predicts response and prognosis in breast cancer patients underwent neoadjuvant chemotherapy.

Zhang C, Wu F, Lu X, Wang S, Wu M, Chen N Front Immunol. 2024; 15:1437193.

PMID: 39403373 PMC: 11471483. DOI: 10.3389/fimmu.2024.1437193.

Plasma Cell-Free DNA Concentration and Fragmentomes Predict Neoadjuvant Chemotherapy Response in Cervical Cancer Patients.

Peng T, Zhang H, Li L, Cao C, Xu M, Liu X Adv Sci (Weinh). 2024; 11(43):e2309422.

PMID: 39319610 PMC: 11578340. DOI: 10.1002/advs.202309422.